{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:19:31Z","timestamp":1770779971873,"version":"3.50.0"},"reference-count":19,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40425-017-0267-9","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T13:35:10Z","timestamp":1500903310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition"],"prefix":"10.1136","volume":"5","author":[{"given":"Quaovi","family":"Sodji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kandy","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavuri","family":"Sravan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1450-087X","authenticated-orcid":false,"given":"Jigarkumar","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,8,15]]},"reference":[{"key":"267_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00000478-199501000-00001","volume":"19","author":"CJ Davis","year":"1995","unstructured":"Davis CJ, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma-the 7th sickle-cell nephropathy. Am J Surg Pathol. 1995;19:1\u201311.","journal-title":"Am J Surg Pathol"},{"key":"267_CR2","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.5489\/cuaj.2373","volume":"9","author":"R Iacovelli","year":"2015","unstructured":"Iacovelli R, Modica D, Palazzo A, Trenta P, et al. Clinical outcome and prognostic factors in renal medullary carcinoma: a pooled analysis from 18 years of medical literature. Can Urol Assoc J. 2015;9:E172\u20137.","journal-title":"Can Urol Assoc J"},{"key":"267_CR3","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/pbc.25592","volume":"62","author":"O Alvarez","year":"2015","unstructured":"Alvarez O, Rodriguez MM, Jordan L, Sarnaik S. Renal medullary carcinoma and sickle cell trait: a systematic review. Pediatr Blood Cancer. 2015;62:1694\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"267_CR4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3892\/ol.2015.3891","volume":"11","author":"ZS Shi","year":"2016","unstructured":"Shi ZS, Zhuang Q, You RX, Li YM, Li J, Cao DR. Clinical and computed tomography imaging features of renal medullary carcinoma: a report of six cases. Oncol Lett. 2016;11:261\u20136.","journal-title":"Oncol Lett"},{"key":"267_CR5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.eucr.2015.07.011","volume":"3","author":"P Colombo","year":"2015","unstructured":"Colombo P, Smith SC, Massa S, Renne SL, Brambilla S, et al. Unclassified renal cell carcinoma with Medullary phenotype versus renal Medullary carcinoma: lessons from diagnosis in an Italian man found to harbor sickle cell trait. Urol Case Rep. 2015;3:215\u20138.","journal-title":"Urol Case Rep"},{"key":"267_CR6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/ajmg.c.30160","volume":"148C","author":"PL Kavanagh","year":"2008","unstructured":"Kavanagh PL, Wang CJ, Therrell BL, Sprinz PG, Bauchner H. Communication of positive newborn screening results for sickle cell disease and sickle cell trait: variation across states. Am J Med Genet C Semin Med Genet. 2008;148C:15\u201322.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"267_CR7","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI31405","volume":"117","author":"JB Swann","year":"2007","unstructured":"Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117:1137\u201346.","journal-title":"J Clin Invest"},{"key":"267_CR8","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, et al. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803\u201313.","journal-title":"N Engl J Med"},{"key":"267_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-016-0206-1","volume":"5","author":"KE Beckermann","year":"2017","unstructured":"Beckermann KE, Jolly PC, Kim JY, Bordeaux J, Puzanov I, Rathmell WK, Johnson DB. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. J Immunother Cancer. 2017;5:1.","journal-title":"J Immunother Cancer"},{"key":"267_CR10","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.eururo.2015.09.027","volume":"69","author":"J Calderaro","year":"2016","unstructured":"Calderaro J, Masliah-Planchon J, Richer W, Maillot L, Maille P, et al. Balanced translocations disrupting SMARCB1 are Hallmark recurrent genetic alterations in renal Medullary carcinomas. Eur Urol. 2016;69:1055\u201361.","journal-title":"Eur Urol"},{"key":"267_CR11","doi-asserted-by":"publisher","unstructured":"Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, et al. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2016; doi: 10.1111\/bju.13705 .","DOI":"10.1111\/bju.13705"},{"key":"267_CR12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/pbc.20292","volume":"44","author":"JJ Strouse","year":"2005","unstructured":"Strouse JJ, Spevak M, Mack AK, Arceci RJ, et al. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer. 2005;44:407\u201311.","journal-title":"Pediatr Blood Cancer"},{"key":"267_CR13","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/pbc.22611","volume":"55","author":"A Walsh","year":"2010","unstructured":"Walsh A, Kelly DR, Vaid YN, Hilliard LM, Friedman GK. Complete response to Carboplatin, Gemcitabine, and Paclitaxel in a patient with advanced metastatic renal Medullary carcinoma. Pediatr Blood Cancer. 2010;55:1217\u201320.","journal-title":"Pediatr Blood Cancer"},{"key":"267_CR14","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1200\/JCO.2005.05.0344","volume":"24","author":"EA Ronnen","year":"2006","unstructured":"Ronnen EA, Kondagunta GV, Motzer RJ. Medullary renal cell carcinoma and response to therapy with Bortezomib. J Clin Oncol. 2006;24:e14.","journal-title":"J Clin Oncol"},{"key":"267_CR15","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/pbc.25832","volume":"63","author":"S Batra","year":"2016","unstructured":"Batra S. Is there a role for Antiangiogenic therapy in renal Medullary carcinoma? Pediatr Blood Cancer. 2016;63:746\u20137.","journal-title":"Pediatr Blood Cancer"},{"key":"267_CR16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/1756287216656811","volume":"8","author":"A Mennitto","year":"2016","unstructured":"Mennitto A, Grassi P, Ratta R, Verzoni E, Prisciandaro M, Procopio G. Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. Ther Adv Urol. 2016;8:319\u201326.","journal-title":"Ther Adv Urol"},{"key":"267_CR17","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","volume":"101","author":"RH Thompson","year":"2004","unstructured":"Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong HD, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004;101:17174\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"267_CR18","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/annonc\/mdu445","volume":"25","author":"TK Choueiri","year":"2014","unstructured":"Choueiri TK, Fay AP, Gray KP, Callea M, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014;25:2178\u201384.","journal-title":"Ann Oncol"},{"key":"267_CR19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, et al. Genomic and Transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35\u201344.","journal-title":"Cell"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-017-0267-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:42:44Z","timestamp":1601055764000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-017-0267-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,15]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["267"],"URL":"https:\/\/doi.org\/10.1186\/s40425-017-0267-9","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,15]]},"article-number":"62"}}